A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy

Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients

NCT03251768 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia

NCT00497809 ·Status: COMPLETED ·Phase: PHASE2

The Oral Cavity as a Source of Febrile Neutropenia

NCT02702583 ·Status: COMPLETED

A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

NCT02521441 ·Status: COMPLETED ·Phase: PHASE2

Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia

NCT01658956 ·Status: UNKNOWN ·Phase: PHASE2

Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated

NCT02921191 ·Status: COMPLETED

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

NCT04187898 ·Status: COMPLETED ·Phase: PHASE1

Treatment for Elderly Patients With High Risk Breast Cancer

NCT00117910 ·Status: COMPLETED ·Phase: PHASE3

An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca

NCT04662892 ·Status: UNKNOWN

G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer

NCT00771433 ·Status: COMPLETED ·Phase: PHASE2

A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)

NCT02428114 ·Status: COMPLETED

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

NCT03246009 ·Status: COMPLETED ·Phase: PHASE1

Telpegfilgrastim Injection to Reduce the Risk of Neutropenia in Patients With Solid Tumor

NCT07096479 ·Status: RECRUITING

Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

NCT03846414 ·Status: UNKNOWN

Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

NCT02178475 ·Status: COMPLETED

Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia

NCT02536599 ·Status: UNKNOWN

Various G-CSF Regimens to Prevent Infection During Chemotherapy

NCT00536081 ·Status: COMPLETED ·Phase: PHASE3

G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

NCT03793205 ·Status: UNKNOWN ·Phase: PHASE4

G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy

NCT00770172 ·Status: COMPLETED ·Phase: PHASE3

Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

NCT06510868 ·Status: RECRUITING

Profiling Neutrophil Counts in Patients on Chemotherapy

NCT02806557 ·Status: UNKNOWN

Evaluating Treatment of Anemia in Subjects With Non-Myeloid MalignanciesReceiving Multicycle Chemotherapy

NCT00111462 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia

NCT02761460 ·Status: UNKNOWN ·Phase: PHASE3

Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)

NCT02685111 ·Status: TERMINATED ·Phase: PHASE2

A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

NCT02119715 ·Status: COMPLETED ·Phase: PHASE2